Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,366 total articles
Altimmune ($ALT) is worth revisiting on a trade basis. Recent 48-week MASH data and a refreshed balance sheet remove near-term financing as the main drag. A potential AUD (alcohol use disorder) readout expected in Q3 2026 is a binary catalyst that could re-rate the stock toward prior highs if positive. We upgrade to a tactical long with defined ent…
Shift4 (FOUR) has evolved beyond card rails into a structurally defensive niche after the Global Blue acquisition. Strong free cash flow, accelerating payment volumes, and insider buying create a high-conviction long. Risks include heavy leverage, integration execution and macro pressure on travel spend. I recommend a long entry at $51.47 with $46.…
IREN has reappeared in takeover chatter. The market is pricing in a deal that is not yet signed — creating a defined, asymmetric trade: buy weakness now with a strict stop and a mid-term target reflecting a likely takeover premium. This idea sizes for conviction but includes a clear exit if the paperwork never arrives.
Universal Music's advantages in catalog breadth, artist relationships and emerging AI licensing create a clearer path to margin expansion and revenue upside than two years ago. This note lays out an actionable long trade with entry, stop and targets and explains the key catalysts and risks that should move the stock.
First Quantum (FQVLF) has swung from panic to opportunity. The stock trades well below its 52-week high despite a market-cap of roughly $22.1B and a clear exposure to the copper story. Political perception has weighed on the multiple; with commodity tailwinds, rate support and an improving technical base, this is a risk-managed long idea targeting …
American Financial Group has the balance sheet and free cash flow to support baby-bond related capital moves. With the stock trading at a reasonable multiple, a buy here offers roughly 15% upside to my target while collecting a mid-single-digit yield. I outline an actionable trade plan, key catalysts and risks.
Crescent Energy is trading at roughly 8x price-to-free-cash-flow with an implied FCF yield north of 12% and a >5% cash distribution. With enterprise-value multiples under 5x EBITDA and projected merger synergies of $90-100M, this name looks attractively priced versus the risk of a cyclical earnings drag. I present an actionable long trade with entr…
Coinbase is the dominant regulated gateway for institutions entering crypto markets. Recent weakness offers an opportunity to buy a prime-brokerage style business exposed to rising institutional flows, stablecoin partnerships, and onchain product revenue. This trade targets a recovery toward $220 over 180 trading days with a strict stop at $145 to …
ANTA Sports (ANPDF) sits at a technical and sentiment inflection point. Deeply oversold indicators, episodic heavy shorting, and a plausible M&A narrative tied to Puma create a tradeable asymmetric risk-reward. This plan outlines an entry at $8.87, a stop at $7.50, and a $16.50 target with horizon clarity and explicit risks.
Lumentum (LITE) sits at the center of the silicon-photonics story: huge headline investments, a factory buildout, and promises of hyperscaler orders. The market has dutifully bid the multiple to nosebleed levels - P/E north of 120, EV/EBITDA ~92x and FCF yield around 0.2%. That leaves room for a tactical short over the next 45 trading days if order…
Palo Alto Networks (PANW) sits at the intersection of traditional network security and the emergent need to defend AI attack surfaces. The stock pulled back from $357.53 to trade near $345.81 after a one-day gap, creating a tactical entry for a mid-term swing. Valuation is rich but defendable given platform positioning, recurring revenue mix and so…
Novartis ($156.74) is actively rebuilding its innovation engine with bolt-on M&A and late-stage assets. A clinical readout for a late-stage program (pelacarsen) is expected imminently, and the company just agreed to acquire Myricx Bio for up to $1.5 billion (07/06/2026) to beef up its ADC payload capabilities. We view the risk/reward as favorable f…
Uber's platform economics, sizable free cash flow, and explicit supply deals with autonomous vehicle makers mean robotaxis are a real earnings lever, not just a headline. I lay out an actionable long trade with entry, stop, targets, catalysts and risks tied to deployments and regulation.
Strata Critical Medical (SRTA) combines air logistics with newly integrated perfusion and donor services to create a vertically aligned organ-transplant platform. The Keystone Perfusion deal and guidance for high-teens Adjusted EBITDA growth underpin a mid-term long trade: buy SRTA around current levels with a $7.00 target and a disciplined stop at…
CareDx is sharpening into a higher-margin transplant diagnostics leader. A $170M sale of its Lab Products business and a strong preliminary Q1 2026 update (revenue +39% YoY; Testing Services +48%) create a realistic mid-term trade: buy at current levels with a $38 target and a $24 stop. The company is cash-flow positive and trading at a market cap …
Micron's position as a leading supplier of DRAM and HBM to hyperscalers, backed by strong profitability, free cash flow, and a market cap of roughly $1.11T, suggests the current pullback is an opportunity. I outline a mid-term long trade (45 trading days) that leans on continued AI-driven HBM tightness, upcoming earnings cadence, and industry capac…
Rogers Communications (RCI) is trading near the low end of its 52-week range with a sub-4x P/E, a 4.6% yield and deep technical oversold signals. Recent corporate moves - including taking full control of major sports assets - create a catalyst runway while valuation provides a margin of safety. This trade idea lays out an entry, stop and target wit…
Taylor Devices (TAYD) is a niche industrial manufacturer of shock absorption and energy-control hardware with no debt, double-digit returns on capital, and a modest valuation by several measures. The story is simple: durable cash flow, improving margins, and growing aerospace/defense sales that the market hasn't fully priced. This trade idea outlin…
Newmont (NEM) trades like a deep-value gold major after a painful June drawdown. The balance sheet, free cash flow and buyback activity make it a reasonable tactical long, but higher costs and falling gold prices keep it from being my top pick. This trade targets a recovery into mid-$100s over a 45 trading-day horizon with a strict stop at $90.
Suncor (SU) is trading near $55 after a period of weakness that reflects headline sensitivity rather than a change in the company’s core cash-generating assets. With a market cap near $64.8B, a 3%+ dividend yield, an enterprise value of roughly $83.8B and negative free cash flow last reported at -$841M, the opportunity today is asymmetric: downside…
Boeing's path back to normalized production is the most actionable lever left for the stock. This trade idea buys into measurable improvements on the factory floor and the backlog cadence, with a defined entry at $220, a $280 target and a $190 stop.
Ciena has surged roughly 80% year-to-date but the balance sheet, cash flow generation and direct exposure to the AI infrastructure build make the stock a compelling mid-term swing trade. Valuation is rich on headline multiples, yet modest free cash flow yield, strong liquidity (current ratio 2.73) and secular demand for optical networking justify a…
ON Semiconductor (ON) is commonly pegged as a cyclical automotive supplier. That’s a fair starting point, but recent strategic moves - most notably the $7B Synaptics acquisition - and growing AI/data-center exposure shift the company toward structural growth in edge AI, sensing and power electronics. With a market cap of roughly $36.85B, $1.18B in …
Iberdrola offers a mix of regulated utility stability and predictable renewable growth. This trade targets steady upside over the next 180 trading days with a defined stop to manage grid and regulatory risks.
Marvell's deep portfolio in data-center connectivity, custom ASICs and optics, plus robust free cash flow and a $218B market cap, make it a better asymmetric trade than smaller peers like Credo for investors who want AI-infrastructure exposure. Valuation is rich, so this is a disciplined swing trade with a defined stop and a mid-term horizon.
